2. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290–6.
3. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447–53.
4. Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 2007;32:193–9.
5. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 2007;7:151–60.
6. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513–20.
7. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086–94.
10. Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017;35:1884–90.
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
16. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22:1583–8.
17. Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017;376:1027–37.
18. Malmstrom A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–26.
19. Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency Randomized Phase III Study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2015;33:4145–50.
20. Scoccianti S, Krengli M, Marrazzo L, et al. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiol Med 2018;123:48–62.
21. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 2013;39:350–7.
23. Wee CW, Kim IH, Park CK, et al. Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection? J Neurooncol 2020;148:57–65.
25. Santacroce A, Walier M, Regis J, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery 2012;70:32–9.
26. Kuhn EN, Taksler GB, Dayton O, et al. Is there a tumor volume threshold for postradiosurgical symptoms?: a single-institution analysis. Neurosurgery 2014;75:536–45.
27. Morita A, Coffey RJ, Foote RL, Schiff D, Gorman D. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. J Neurosurg 1999;90:42–9.
29. Pinzi V, Marchetti M, Viola A, et al. Hypofractionated radiosurgery for large or in critical-site intracranial meningioma: results of a phase 2 prospective study. Int J Radiat Oncol Biol Phys 2023;115:153–63.
30. Gagliardi F, De Domenico P, Snider S, et al. Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis. Neurosurg Rev 2023;46:71.
31. Combs SE, Baumert BG, Bendszus M, et al. ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiother Oncol 2021;156:80–94.
35. Zhang M, Ho AL, D’Astous M, et al. CyberKnife stereotactic radiosurgery for atypical and malignant meningiomas. World Neurosurg 2016;91:574–81.
36. Kowalchuk RO, Shepard MJ, Sheehan K, et al. Treatment of WHO grade 2 meningiomas with stereotactic radiosurgery: identification of an optimal group for SRS using RPA. Int J Radiat Oncol Biol Phys 2021;110:804–14.
37. Shepard MJ, Xu Z, Kerans K, Li C, et al. Stereotactic radiosurgery for atypical (World Health Organization II) and anaplastic (World Health Organization III) meningiomas: results from a multicenter, international cohort study. Neurosurgery 2021;88:980–8.
38. Nieder C, Andratschke NH, Grosu AL. Re-irradiation for recurrent primary brain tumors. Anticancer Res 2016;36:4985–95.
39. Kazmi F, Soon YY, Leong YH, Koh WY, Vellayappan B. Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol 2019;142:79–90.
41. Moller S, Munck Af Rosenschold P, Costa J, et al. Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. Radiother Oncol 2017;125:223–7.
44. Navarria P, Pessina F, Clerici E, et al. Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. Radiother Oncol 2022;167:89–96.
45. Tsien CI, Pugh SL, Dicker AP, et al. NRG Oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol 2023;41:1285–95.
46. Bergman D, Modh A, Schultz L, et al. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. J Neurooncol 2020;148:353–61.
48. Gogineni E, Rana Z, Vempati P, et al. Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer. Head Neck 2020;42:2880–6.
49. Bonomo P, Desideri I, Loi M, et al. Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: is de-intensified, hypofractionated radiotherapy a feasible strategy? Oral Oncol 2017;74:142–7.
50. De Felice F, Vetrone L, Bulzonetti N, et al. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma. Med Oncol 2019;36:68.
52. Bledsoe TJ, Noble AR, Reddy CA, et al. Split-course accelerated hypofractionated radiotherapy (SCAHRT): a safe and effective option for head and neck cancer in the elderly or infirm. Anticancer Res 2016;36:933–9.
53. Benhmida S, Sun R, Gherga E, et al. Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers: a retrospective study of 75 cases. Cancer Radiother 2020;24:812–9.
54. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009;75:1493–500.
55. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol 2011;34:165–72.
56. Vargo JA, Ward MC, Caudell JJ, et al. A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer. Int J Radiat Oncol Biol Phys 2018;100:595–605.
59. Vargo JA, Heron DE, Ferris RL, et al. Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume. Head Neck 2014;36:1349–55.
60. Dogan OY, Yaprak G, Ozyurt H, et al. Is fractionated robotic stereotactic body radiosurgery optional salvage treatment for the re-irradiation of locally recurrent nasopharyngeal carcinoma? J Cancer Res Ther 2022;18:66–71.
62. Echevarria MI, Yang GQ, Chen DT, et al. Phase 1 dose escalation of stereotactic body radiation therapy and concurrent cisplatin for reirradiation of unresectable, recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2023;117:341–7.
64. Karam I, Yao M, Heron DE, et al. Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Future Oncol 2017;13:603–13.